Dear editor,
Vaccines are the most efficient and effective means to prevent infectious diseases, but improving the long-term protective efficacy is still a major challenge in contemporary vaccine development.1 The waning immunity varies depending on the diversification of the pathogen and the number of booster doses.1 Strategies to overcome this warrant is using adjuvants that amplify the immune response, and drive the production of memory B and T cells or long-lived plasma cells that recognize the pathogen for durable protection.2,3,4 Although existing adjuvants have achieved promising results, research on generating durable protective immunity is lacking in promoting vaccine development and staying ahead of global pandemics such as coronavirus disease 2019 (COVID-19). The precisely designed nanoadjuvants can enhance lymph node targeting and increase antigen-presenting cell (APCs) uptake, achieving the co-delivery of adjuvants and antigens and activating innate and adaptive immune responses.5 Previously, we reported a manganese nanoadjuvant (MnARK) and receptor-binding domain (RBD) monomer antigen formulated nanovaccine.6 MnARK transported antigens to lymph nodes, activated the STING pathway, elicited strong neutralizing abilities and increased immune memory T cell percentage against the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).6 Regarding the long-term protection potential of MnARK for subunit vaccine development, we further explored the durable immune regulation abilities of MnARK to a SARS-CoV-2 RBD dimer antigen, which has been used in an approved COVID-19 subunit vaccine ZF2001 with aluminum adjuvant (alum).7,8 TEM result revealed that RBD dimer could interact with BSA on MnARK surface and epitope can be well preserved (Supplementary Fig. 1a). The size and zeta potential of MnARK-RBD dimer nanovaccine was ~58 nm and -14 mV, respectively (Supplementary Fig. 1b, c).
To evaluate the immunogenicity of MnAKR-based nanovaccine, we intramuscularly (i.m.) immunized mice with 10 μg dose of RBD dimer formulated with MnARK or commercial alum adjuvant. The antibody (Ab) responses at various time points for up to 360 days after the prime vaccination were measured (Fig. 1a). The MnARK-based nanovaccine induced the most rapid Ab response, showing detectable anti-RBD antibodies (immunoglobulin M [IgM] and immunoglobulin G [IgG]) two weeks after the second vaccination (Fig. 1b, Supplementary Fig. 1d). The MnARK-based nanovaccine could elicit RBD-specific IgG up to endpoint titer of ~106 after the third vaccination, which was significantly higher than that induced by the alum-based vaccine (P < 0.001). Excitingly, durable and enhanced titers induced by MnARK were observed for the entire study (Fig. 1b). The Ab responses were similar from day 90 to day 360 across all animals receiving MnAKR-based nanovaccine. In contrast, a substantial response contraction was observed in animals immunized with alum-based vaccine. The IgG titer induced by the MnARK-based nanovaccine is 64 times and 46 times than that of the alum-based vaccine at day 240 and 360, respectively (Fig. 1b). Sera at day 56 and 360 were further tested for the neutralizing activities against live SARS-CoV-2 virus (prototype strain). Consistently, high levels of neutralizing antibody (NAb) were detected in RBD dimer-vaccinated mice using MnARK adjuvant, either at day 56 or 360 (Fig. 1c). MnARK-based nanovaccine outperformed alum-based vaccine to elicit high levels of NAbs with geometric mean titer (GMT) of 50% neutralization titer up to 2,353 at day 56. Encouragingly, at day 360, MnARK nanovaccine group maintained NAb titers at GMT of 512, 3 times than that of the alum-based vaccine group (GMT, 147) (Fig. 1c), suggesting the potential superiority of MnARK formulated nanovaccine in producing long-term immune responses.
As establishing the germinal center (GC) response is critical for generating plasma cells and memory B cells capable of mediating durable protective immunity,3,9 we assessed whether the MnARK-based nanovaccine vaccination elicits a GC reaction for the capacity of responding B cells. We observed a striking increase in percentages of GC B cells two weeks after final vaccination with MnARK-based nanovaccine, demonstrating the advantages of MnARK over alum in promoting activation of antigen-specific B cells (Fig. 1d). Visualization of GCs in the lymph nodes remained detectable at least up to 90 days in animals vaccinated with MnARK relative to alum-based vaccine (Fig. 1e). This demonstrates that MnARK preferentially enhances the persistence of GC response, which is essential to the establishment of durable and broad immunity against virus and is a crucial metric of vaccine efficacy. Of note, MnARK-based nanovaccine induced a strikingly high level of memory B and T cells in spleens at day 90 post-vaccination (Fig. 1f). Memory B cells can be expanded and differentiated into antibody-secreting cells upon re-experience of antigen, playing a fundamental role in defending against viruses.9,10 Overall, these results indicate the durable SARS-CoV-2-specific immune response induced by MnARK-based vaccine, presenting deep profiling of anti-SARS-CoV-2 B cell responses.
To determine how MnARK influenced the immune response, we first vaccinated mice with Cy5-labeled RBD dimer via i.m. route to test the in vivo trafficking of antigen. MnARK induced an antigen depot comparable with that of alum at the injection sites (Supplementary Fig. 1e) and antigens undergo rapid metabolism through the kidneys and liver (Supplementary Fig. 1f). Exploiting the characteristics of albumin as a transporter and biotemplate, MnARK transported more RBD dimer to lymph nodes (Fig. 1g, h, Supplementary Fig. 2a), simultaneously promoting the uptake of APCs (Fig. 1i). Gating to firstly identify all dimer-positive cells, the result revealed that, among the RBD dimer-positive population in MnARK group, almost 36% were dendritic cells (DCs) and 33% were B cells, while an additional 20% were leukocytes of neither macrophages or T cells (Fig. 1j). DC and B cells seem to be nearly co-equal in their enhanced antigen uptake, associated with persistent activation of DCs (Supplementary Fig. 2b) and B cells (Fig. 1d–f). The stimulation of DCs by MnARK was evaluated using bone marrow dendritic cell (BMDC) in vitro. As shown in Supplementary Fig. 2b–e, MnARK-based nanovaccine significantly increased CD86+ and CD80+ expressions and pro-inflammatory cytokines levels compared with the free antigens and alum-based vaccine. And the higher the major histocompatibility complex class II/I (MHC II/MHC I)-presenting cells among the treated BMDCs demonstrated the enhanced cross-presentation of antigens. Of note, compared to alum, MnARK showed a 4-fold increase in the cellular uptake of RBD dimer in B cells (Fig. 1j), demonstrating the advantages of MnARK over alum in promoting activation of antigen-specific B cells. We used confocal microscopy to visualize antigen distribution in lymph nodes to confirm this flow cytometry analysis result. MnARK group can be seen in both DC and B cells (Supplementary Fig. 2a). Altogether, MnARK is superior to alum in increasing the cellular uptake of antigen in most APCs in lymph nodes, which play a crucial role in activating antigen-specific T and B cells.
To further investigate the features of MnARK-induced immunity, we performed mass cytometry (CyTOF) analysis of CD45+ cells in muscles and lymph nodes isolated from mice in the MnARK vaccinated group and the unvaccinated control group (Fig. 1k). In-depth studies of the 41 markers (Supplementary Table 1), expression profiles of immune cell clusters were visualized in a heatmap (Supplementary Fig. 2f), with 28 and 35 cell clusters identified in muscles and lymph nodes, respectively. The CD45+ subpopulations could be distinguished in the comprehensive single-cell visualization on t-distributed stochastic neighbor embedding (t-SNE) plots (Fig. 1l, o). Apparent alteration of immune cell subsets was observed in the MnARK vaccinated group compared with control group. Firstly, T cells, B cells and myeloid cells changed obviously in the muscles shortly at 6 h after injection (Fig. 1m). Specifically, DCs, B cells, T helper (Th) cells, cytotoxic T lymphocytes (CTL), neutrophils, and natural killer (NK) cells were recruited to the injection site. Notably, the expressions of the MHC II molecules on DCs and B cells were upregulated (Fig. 1n), which was beneficial for the antigen presentation. Moreover, in the lymph nodes at 35 d post immunization, we found significant expansion of activated DC cells, memory T cells and mature B cells (Fig. 1p, q). These results indicated that MnARK-based nanovaccine enhanced the magnitude of both humoral and CD8+ T cell responses. Consistent with the CyTOF results, the numbers of IFN-γ-secreting cells increased by 7.7-fold in the spleen than that of alum-based vaccine (Supplementary Fig. 2g). Sera from MnARK-based nanovaccine immunized animals showed significantly higher IgG2c-to-IgG1 titer ratio (Supplementary Fig. 2h) than that of alum-based vaccine. Correspondingly, intracellular cytokine staining (ICS) measurements of mouse splenocytes demonstrated that the MnARK-based nanovaccine induced more robust TH1 responses, which was shown by significantly higher frequencies of IFN-γ+, TNF-α+ and IL-2+ CD4+ T cell and CD8+ T cells, compared to alum-based vaccine (Supplementary Fig. 2i, j). Therefore, MnARK nanoadjuvant can induce a more robust TH1 cell response than alum adjuvant.
Our data showed steady maintenance of the antibody titer over 360 days through a judicious combination of antigen and MnARK adjuvant. Notably, MnARK generates potent CD8+ T cell responses, which are not optimally induced by commonly used alum adjuvants in vaccines. In addition, MnARK can target lymph nodes and enhance the uptake of antigen by B cells to promote B cell activation and prolong GC persistence, which presumably contribute to the magnitude and durability of humoral immunity (Supplementary Fig. 3). Several immunological outcomes in MnARK group could have contributed to successful induction of durable immune response: (1) promotion of antigen uptake by DCs and B cells (Fig. 1j), key cell types in sensing adjuvants to enhance antibody responses to vaccination. (2) successful induction of Th1 polarized CD4+ T cells (Supplementary Fig. 2g–j). The magnitude of the T helper cells migrate to the interface between the B cell follicle and the T cell area, where they stimulate antigen-activated B cells. And finally, 3) directly activating B cells of the adaptive immune system (Fig. 1n, q). Strategies to affect the molecular signatures of B cells by adjuvants is still limited. Further studies investigating the direct impact of MnARK on B cells could identify mechanisms that improve durable immune response.
Data availability
The data supporting the conclusion of this study can be required from the corresponding authors.
Change history
16 January 2024
A Correction to this paper has been published: https://doi.org/10.1038/s41392-024-01739-x
References
Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to new developments. Nat. Rev. Immunol. 21, 83–100 (2021).
Zhao, T. et al. Vaccine adjuvants: mechanisms and platforms. Signal Transduct. Target Ther. 8, 283 (2023).
Yin, Q. et al. A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2. Nat. Mater. 22, 380–390 (2023).
Wu, Y. et al. A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Sci. Transl. Med. 13, eabg1143 (2021).
Chen, X. et al. Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity. Nat. Commun. 14, 4584 (2023).
Wang, Y. et al. Engineering a self-navigated MnARK nanovaccine for inducing potent protective immunity against novel coronavirus. Nano Today 38, 101139 (2021).
Dai, L. et al. A universal design of Betacoronavirus vaccines against COVID-19, MERS, and SARS. Cell 182, 722–733 (2022).
Dai, L. et al. Efficacy and safety of the RBD-dimer-based Covid-19 vaccine ZF2001 in adults. N. Engl. J. Med. 386, 2097–2111 (2022).
Laidlaw, B. & Ellebedy, A. The germinal centre B cell response to SARS-CoV-2. Nat. Rev. Immunol. 22, 7–18 (2022).
Hooman, A. M. A. et al. COVID-19: a systematic review and update on prevention, diagnosis, and treatment. Med. Comm. 3, e115 (2022).
Acknowledgements
This work was supported by the National Basic Research Program of China (2022YFA1603701 and 2021YFA1200900), the National Natural Science Foundation of China (82341044, 22027810), the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science (CIFMS 2019-I2M-5-018), Strategic Priority Research Program of the Chinese Academy of Sciences (XDB36000000), and the China Postdoctoral Science Foundation (2021TQ0085, 2022M720932). We thank Xuemei Zhou and Yaling An from the Institute of Microbiology for their help in the preparation of RBD dimer antigen. And we thank Xi Chen and Wenjiao Fu from the National Center for Nanoscience and Technology, who helped with the animal experiments.
Author information
Authors and Affiliations
Contributions
C.C., Y.W. and Y.Z. conceived the project and designed the experiments. C.C. and Y.W. supervised the study. L.D. and F.G. provided the RBD dimer antigen. Y.W. and X.W. prepared and characterized the MnARK adjuvant. M.G. and Z.C. performed animal experiments. M.C., Y.W., and M.G. performed CyTOF experiments and data analysis. J.S. performed live virus neutralization experiment. M.G., Y.W. and C.C. wrote the manuscript. All authors discussed the results and commented on the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics
All the protocols of all the animal experiments were approved by the Animal Care and Use Committee of National Center for Nanoscience and Technology.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Guo, M., Cao, M., Sun, J. et al. Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine. Sig Transduct Target Ther 8, 462 (2023). https://doi.org/10.1038/s41392-023-01718-8
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41392-023-01718-8
This article is cited by
-
Correction: Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine
Signal Transduction and Targeted Therapy (2024)